Peptide Library

In clinical trials

Digestive & weight

Survodutide

Evidence

Clinical trials

Class

Dual glucagon and GLP-1 receptor agonist

/

Survodutide

KEY TAKEAWAY

Survodutide is a peptide that activates both the glucagon and GLP-1 receptors. Boehringer Ingelheim is developing it for obesity and fatty liver disease. Survodutide is not FDA-approved and is being tested in late-stage clinical trials.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Dual glucagon and GLP-1 receptor agonist

Being studied for

Studied for obesity and fatty liver disease (MASH)

Key fact

Survodutide is not FDA-approved and is being tested in late-stage clinical trials.

Route

Weekly subcutaneous injection in trials

Evidence strength

Clinical trials

What it is

What it is

Survodutide is a peptide that activates both the glucagon and GLP-1 receptors. Boehringer Ingelheim is developing it for obesity and fatty liver disease.

How it works

How it works

GLP-1 activity reduces appetite, while glucagon activity may increase energy use and lower fat stored in the liver.

Regulatory status

Regulatory status

Survodutide is not FDA-approved and is being tested in late-stage clinical trials.

What it is used for

What it is used for

Studied for obesity and fatty liver disease (MASH).

Side effects and risks

Side effects and risks

Nausea, vomiting and diarrhea were the most common effects in trials.

Citations

Citations

Survodutide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo